Coronavirus Vaccine Phase 1 Trial Results Released

Daniel Culver, DO, comments on early study results that suggest an experimental COVID-19 vaccine is safe and activates the immune system.

Media Downloads

CCNS health and medical content is consumer-friendly, professional broadcast quality (available in HD), and available to media outlets each day.

Additional Assets

*Email us for video download password Content is property of Cleveland Clinic and for news media use only.

Media Contact

We're available to shoot custom interviews & b-roll for media outlets upon request.

CLEVELAND – The world is waiting for an effective vaccine for COVID-19.

A number of vaccines are in development – but testing takes time.

One manufacturer just released early study results for a novel RNA-based vaccine.

Cleveland Clinic’s Daniel Culver, DO, was not involved in the research, but said data shows the vaccine seems safe and appears to activate the immune system.

“This is a Phase 1 trial. It’s showing that patients respond, that patients are responding in the way you would hope,” he said.

The small Phase 1 study looks at safety and vaccine response in 45 healthy adult volunteers.

Results suggest that the vaccine is well tolerated and may cause mild side effects including – fatigue, headache, chills, muscle pain and injection site pain.

The data also show that the vaccine triggered the immune system to produce antibodies to potentially fight COVID-19.

Now, investigators need to prove it can prevent infection.

Dr. Culver said vaccines need to pass two more stages of research before they’re considered viable.

The early study results are encouraging, but he reminds us there’s a long way to go.

“The next steps are to prove that this actually is durable, effective at preventing infection and will be a useful strategy for populations,” said Dr. Culver.

According to Dr. Culver, despite promising findings in early Phase 1 trials, most vaccines don’t make it through the next two rounds of testing.

Complete results of the study can be found in the New England Journal of Medicine.

For Journalists Only

Sign up below to be added to our Daily Health Stories distribution list.

You can also follow us on Twitter @CCformedia to receive real-time updates when new content is posted.